Dossier · Public company · 2 independent sources
Evogene Ltd.
Last updated: Jul 31, 2026
Public Israeli computational chemistry and biology company developing AI-driven small-molecule discovery tools for pharmaceutical and agricultural products, with a focused 2026 strategy centered on its ChemPass AI platform.
Visit WebsiteCompany Overview
Evogene is a Rehovot-based public company whose current strategy is centered on ChemPass AI™, a proprietary generative-AI and computational-chemistry engine for designing and optimizing small molecules. The platform is described by the company as being trained on roughly 38 billion molecular structures and as optimizing several product-relevant properties at once, including potency, selectivity, stability, toxicity, ADME, scaffold design, and synthesizability. Its workflow combines literature and data preparation, target modeling, virtual hit screening, analog generation, and prioritization for experimental testing. This is a credible and important problem: discovery programs often fail because activity, selectivity, developability, safety, and manufacturing constraints are optimized sequentially rather than together. Evogene's claims about precision and acceleration are company-reported technology claims, not evidence that a candidate has reached clinical or commercial validation.
The commercial model is a mixture of collaborative research, licensing, co-development, and internally advanced product programs. The principal markets are pharmaceutical discovery and agricultural chemicals, where customers can use computational design to reduce the number of compounds synthesized and tested before selecting leads. Evogene has expanded its collaboration with Google Cloud to integrate AI agents through Vertex AI, and in July 2026 announced a scientific collaboration with South Korea's ELEO to design and prioritize oral PCSK9-pathway inhibitors. These announcements show active business-development and platform-integration work, but they remain early discovery or collaboration signals rather than proof of regulatory approval, recurring software revenue, or a marketed drug. The company reported approximately $3.9 million of 2025 revenue, down from approximately $5.6 million in 2024, so diligence should separate strategic activity from durable commercial traction.
Evogene's operating structure has changed materially. AgPlenus, its agricultural-chemicals subsidiary, was integrated into core operations and resized around the ChemPass platform. The majority of Lavie Bio's activity was acquired by ICL in 2025 and Lavie Bio discontinued operations at the end of the first quarter of 2026. Biomica's operations were scaled down and its lead oncology candidate was licensed to Lishan Pharmaceuticals; Casterra is focused on castor-seed activities in Brazil after reducing operations elsewhere. This streamlining may improve capital discipline and concentrate scarce R&D resources, but it also reduces portfolio breadth and makes the value of ChemPass AI and a small number of pipelines more consequential. The competitive field includes large incumbent agrochemical and pharmaceutical companies, specialized AI-drug-discovery firms, and synthetic-biology platforms with substantially greater capital or larger experimental datasets.
The strongest strategic case is as a computational discovery capability that can help allied food, agricultural, and pharmaceutical ecosystems explore chemical space more efficiently. Crop-protection discovery and resilient agricultural inputs can contribute to food-security planning, while faster small-molecule design may support health and supply-chain resilience. The same general design capabilities could be relevant to security-sensitive chemical or biological research, but Evogene's public materials identify civilian pharmaceutical and agricultural objectives rather than defense contracts or military deployment. Any national-security engagement would therefore require separate diligence on allowed targets, model access, screening and synthesis controls, export compliance, biosafety, cybersecurity, and partner governance. The immediate questions are whether ChemPass-generated candidates reproduce in independent assays, how many programs have reached meaningful preclinical milestones, what current collaborations pay for, and whether the sharply reduced workforce and financing needs can support execution.
Dual-Use Assessment
Evogene's core capability is civilian generative molecular design for pharmaceutical and agricultural chemistry, not a disclosed defense product. It nevertheless has substantive security adjacency: the same computational methods for target modeling, virtual screening, multi-parameter optimization, and candidate prioritization could support resilience-oriented crop protection or other government research, while chemical and biological design access creates governance concerns. No public evidence reviewed here establishes military customers, defense contracts, or operational deployment, so the dual-use conclusion is about capability transfer potential rather than current defense traction.
Strategic Fit Assessment
Evogene is a mature, publicly traded company and therefore does not fit a startup-priority signal. Its technology is strategically interesting because ChemPass AI is being applied across pharmaceutical and agricultural discovery and is being extended with Google Cloud AI-agent workflows. However, the 2025 revenue decline, reduced workforce, discontinued or transferred subsidiary activities, early-stage nature of disclosed collaborations, and financing dependence make commercialization and execution uncertain. This is a diligence subject for platform validation, partnerships, and strategic collaboration, not an investment recommendation.
Strategic Value to U.S.-Israel Alliance
Evogene may offer strategic value as an Israeli computational-discovery capability for agricultural chemistry, pharmaceutical research, and resilience-oriented innovation. Its platform could help partners search chemical space and prioritize experiments with fewer resources, while the agriculture focus is relevant to food-security and supply-chain resilience. The value is conditional: public disclosures do not show defense deployment, and the company must demonstrate that computational outputs translate into reproducible assays, regulated products, and economically meaningful licensing or collaboration revenue. Government or security-sensitive engagement would require controls for model access, target selection, synthesis pathways, data rights, export compliance, biosafety, and cyber risk.
Key Technologies
- ChemPass AI generative molecular-design engine
- 38-billion-structure molecular foundation model
- Multi-parameter optimization for potency, selectivity, ADME, toxicity, stability, and synthesizability
- AI-agent workflows using Google Cloud Vertex AI
- Computational target modeling and virtual screening
- Design-make-test-analyze prioritization workflows
- Computational Predictive Biology platform
Use Cases & Applications
- Early discovery and optimization of small-molecule drug candidates
- Virtual screening and hit-to-lead prioritization
- Design of crop-protection and agrochemical compounds
- Discovery of novel mechanisms or compounds for agricultural disease and weed control
- Partner R&D workflows that reduce synthesis and assay burden
- Food-security and agricultural-resilience research
- Government or security-sensitive chemistry research subject to appropriate controls
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 7 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Evogene company website Official overview of the current pharma and agriculture focus, ChemPass AI positioning, collaborations, and Rehovot address.
- Evogene ChemPass AI Official technical description of the generative engine, molecular foundation model, optimization objectives, and Google Cloud integration.
- Evogene Reports First Quarter 2026 Financial Results Official update on the 2025 strategic transformation, ChemPass focus, subsidiary wind-downs, and 2026 operating direction.
- Evogene Reports Fourth Quarter and Full Year 2025 Financial Results Official financial and operational update covering revenue pressure, AgPlenus integration, Lavie Bio transaction, Biomica scale-down, and Casterra changes.
- Evogene 2025 Form 20-F SEC-filed annual report for 2025, including corporate status, employees, financial condition, business activities, and risk disclosures.
- Evogene and ELEO PCSK9 collaboration Official July 2026 example of a collaborative early-discovery program using ChemPass AI.
- Evogene - Wikipedia Independent summary of company history, subsidiaries, ticker, and market status.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.